Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes

scientific article published on 23 August 2016

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.7326/M16-0476
P932PMC publication ID5125086
P698PubMed publication ID27548583

P50authorMehmet Ali ErgunQ57334076
Clyde B SchechterQ87050955
Diana MigliorettiQ88168881
Amy Trentham-DietzQ88960210
Jeanne S MandelblattQ90278289
Brian L SpragueQ91924355
Karla KerlikowskeQ92299671
Nicolien T van RavesteynQ98198718
Anna N. A. TostesonQ110143968
Aimee M NearQ114374862
Natasha K StoutQ114563134
Jeroen J van den BroekQ114563144
Oğuzhan AlagözQ56654355
Ronald E GangnonQ56810665
P2093author name stringJohn M Hampton
Harry J de Koning
Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network
Young Chandler
P2860cites workRisk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysisQ24628928
Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor statusQ27012792
The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort modelQ27347267
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer SocietyQ27347760
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trialQ27860743
Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the diseaseQ30665466
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the diseaseQ30747351
Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.Q33792616
Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studiesQ33957073
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefitsQ34159375
Prevalence of mammographically dense breasts in the United StatesQ34354391
Chapter 9: The MISCAN-Fadia Continuous Tumor Growth Model for Breast CancerQ61881608
The impact of a breast cancer screening programme on quality-adjusted life-yearsQ68009566
Projecting individualized probabilities of developing breast cancer for white females who are being examined annuallyQ69396132
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999Q79220367
The Wisconsin Breast Cancer Epidemiology Simulation ModelQ79220380
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation StatementQ34508652
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortalityQ34736052
Identifying women with dense breasts at high risk for interval cancer: a cohort studyQ35646902
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsQ35740423
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast CancerQ36090967
Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studiesQ36368636
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of riskQ36460671
Prediction of breast cancer risk based on profiling with common genetic variantsQ36583004
Performance benchmarks for screening mammographyQ36600843
Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortalityQ36619874
Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosisQ36770273
Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening HarmsQ36908218
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapyQ36976948
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectivenessQ37139381
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening StrategiesQ37364628
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal womenQ37480990
Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer.Q37548461
Breast cancer risk associated with benign breast disease: systematic review and meta-analysisQ38338001
Benefits and Harms of Breast Cancer Screening: A Systematic ReviewQ38616415
Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass IndexQ38627432
Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force RecommendationQ38693328
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY thresholdQ39268069
Family history and the risk of breast cancer: a systematic review and meta-analysisQ41495151
Breast-cancer screening--viewpoint of the IARC Working GroupQ41697220
Alcohol consumption and ethyl carbamate.Q42730898
Convergence and Divergence Around Breast Cancer ScreeningQ44026572
Nurses' health study: log-incidence mathematical model of breast cancer incidenceQ44198064
Mammographic screening programmes in Europe: organization, coverage and participationQ45328273
The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods.Q50192553
Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.Q51914599
A breast cancer prediction model incorporating familial and personal risk factors.Q52000310
Retrospective cost-effectiveness analysis of screening mammography.Q53241570
Cost of care for elderly cancer patients in the United States.Q53730492
Modeling the dissemination of mammography in the United StatesQ56940783
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectbreast cancerQ128581
collaborationQ1145523
breast cancer screeningQ17011492
P304page(s)700-712
P577publication date2016-08-23
P1433published inAnnals of Internal MedicineQ564416
P1476titleTailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes
P478volume165

Reverse relations

cites work (P2860)
Q91621376"You probably can't feel as safe as normal women": Hispanic women's reactions to breast density notification
Q57593829Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis
Q92654615Age-based versus Risk-based Mammography Screening in Women 40-49 Years Old: A Cross-sectional Study
Q64880735Assessing Patient Interest in Individualized Preventive Care Recommendations.
Q64914458Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk for Screen-Detected and Interval Cancers: A Case-Control Study.
Q60175951Breast Cancer Incidence by Stage Before and After Change in Screening Guidelines
Q87909686Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening
Q92528444Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification
Q47304201Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
Q51738440Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.
Q57177092Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
Q92437923Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019
Q52350449Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.
Q92307692Exploring the Role of Breast Density on Cancer Prognosis among Women Attending Population-Based Screening Programmes
Q64092231Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease
Q90678404How Do Women View Risk-Based Mammography Screening? A Qualitative Study
Q90690238Interval breast cancer risk associations with breast density, family history and breast tissue aging
Q92006924Personalized breast cancer screening strategies: A systematic review and quality assessment
Q96577047Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Q38984143Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer
Q52648599Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.
Q47094586Simulation modeling for stratified breast cancer screening - a systematic review of cost and quality of life assumptions.
Q55037632The combined effect of mammographic texture and density on breast cancer risk: a cohort study.
Q60175954Trends in breast cancer mortality by stage at diagnosis among young women in the United States
Q58793591Volumetric breast density and risk of advanced cancers after a negative screening episode: a cohort study
Q91594655Willingness to decrease mammogram frequency among women at low risk for hereditary breast cancer

Search more.